As part of a chemoimmunotherapy strategy, Cao et al. developed a hybrid prodrug made up of both camptothecin and the alkylating agent cisplatin to specifically promote DNA damage-associated STING activation in tumor cells [99]. The gene discussed is STING1; the disease is neoplasm.